Basic HTML Version
Background
•
Early generations of DES have reduced restenosis, but have been
associated with an increased risk of late events
•
Efforts to resolve these problems have been made including
improvements in stent platforms, polymer carriers as well as drug
selection
•
A hybrid combination of active and passive coatings on a DES aim to
optimize effectiveness of results and also mediate the threat of late
events
•
The aim of the BIOFLOW-I study was to evaluate the safety and efficacy
of the Orsiro Hybrid Drug Eluting Stent with a bioabsorbable polymer, in
patients with a single de novo lesion in a native coronary artery